Shares of ImmunityBio touched a 52-week low after the company received a refusal-to-file letter from the Food and Drug Administration for a supplemental biologics license application for ...

The RTF letter was unexpected, especially considering the positive feedback and unanimous encouragement ImmunityBio received ...

ImmunityBio's ANKTIVA sBLA for papillary bladder cancer was rejected by the FDA despite prior support, prompting the company to request urgent talks.

ImmunityBio is seeking an urgent meeting with U.S. health regulators after its bladder-cancer treatment application was rejected. The immunotherapy company said Monday that it received a ...

CG Oncology Inc.’s latest research effort to treat bladder cancer is impressing investors.The Irvine-based biopharmaceutical ...

ImmunityBio, Inc. faces stock decline amid fundraising and market selloff. Click to read more on the long-term potential of ...

ImmunityBio (IBRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The dynamic positioning system market is projected to grow from USD 6.36 billion in 2025 to USD 8.65 billion by 2030, registering a CAGR of 6.3% according to a new report by MarketsandMarketstm. The ...

Descartes Systems Group , the global leader in uniting logistics-intensive businesses in commerce, is scheduled to report its first quarter fiscal 2026 financial results after market close on ...

The companies Biohaven, MoonLake Immunotherapeutics, and AIRNA bagged the biggest biotech funding rounds overall in April 2025.

ImmunityBio (IBRX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook ...